Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
C 168.50 -0.88% -1.50
BGNE closed down 0.88 percent on Monday, March 18, 2024, on 52 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Mar 27
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Inside Day Range Contraction 0.00%
NR7 Range Contraction -0.88%
Inside Day Range Contraction -0.88%
Gapped Up Strength -0.88%
Slingshot Bullish Bullish Swing Setup -0.24%
Multiple of Ten Bearish Other -0.24%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
Possible NR7 4 days ago
Possible Inside Day 4 days ago
Down 1% 4 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BeiGene, Ltd. Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Recombination Rp1

Is BGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 272.39
52 Week Low 132.95
Average Volume 299,455
200-Day Moving Average 183.21
50-Day Moving Average 160.31
20-Day Moving Average 163.88
10-Day Moving Average 165.29
Average True Range 7.81
RSI (14) 54.75
ADX 18.75
+DI 28.62
-DI 19.53
Chandelier Exit (Long, 3 ATRs) 161.38
Chandelier Exit (Short, 3 ATRs) 168.43
Upper Bollinger Bands 180.63
Lower Bollinger Band 147.13
Percent B (%b) 0.64
BandWidth 20.44
MACD Line 3.00
MACD Signal Line 2.17
MACD Histogram 0.8343
Fundamentals Value
Market Cap 17.57 Billion
Num Shares 104 Million
EPS -9.23
Price-to-Earnings (P/E) Ratio -18.26
Price-to-Sales 7.07
Price-to-Book 4.07
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 172.18
Resistance 3 (R3) 172.53 171.65 171.56
Resistance 2 (R2) 171.65 170.72 171.48 171.36
Resistance 1 (R1) 170.08 170.14 170.87 169.73 171.15
Pivot Point 169.20 169.20 169.60 169.03 169.20
Support 1 (S1) 167.63 168.27 168.42 167.28 165.85
Support 2 (S2) 166.75 167.69 166.58 165.64
Support 3 (S3) 165.18 166.75 165.44
Support 4 (S4) 164.83